The KPV peptide is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH): lysine, proline, valine — three amino acids, about 342 daltons, at positions 11 through 13 of the parent hormone. Alpha-MSH is itself a 13-residue peptide cut from the precursor protein proopiomelanocortin (POMC), carrying several unrelated jobs at once: pigmentation, feeding behavior, and the modulation of inflammatory signaling.
A three-residue fragment gets its own literature because it separates those jobs. Getting and colleagues (2003) dissected the anti-inflammatory activity of the core and C-terminal alpha-MSH peptides and found KPV's effect mechanistically distinct from the core peptides — a different route, not a weaker version of it. The fragment keeps the anti-inflammatory arm and leaves the pigmentation and feeding arms behind.
Everything that follows is preclinical. Every figure here comes from cell culture, mice, rats, or computational modeling; no completed human clinical trial of KPV exists, and each finding is labeled with its system.
What the KPV peptide is, and what it kept from alpha-MSH
KPV is alpha-MSH(11–13): the last three residues of a 13-residue hormone, studied alone because it retains the parent molecule's anti-inflammatory signaling while lacking its pigmentation and feeding-behavior effects. At roughly 342 daltons it is one of the shortest peptides with a documented biological literature.
Alpha-MSH and its related peptides have been reviewed as a class of anti-inflammatory and immunomodulating agents (Luger and Brzoska, 2007), but the full-length hormone drags its hormonal arms along with it. KPV does not — and its anti-inflammatory activity does not appear to run through the melanocortin receptors MC1R through MC5R at all.
There is a receptor-facing flip side. Nyberg and colleagues (2025) found that building the Lys-Pro-Val motif into larger melanotropin constructs enhanced binding affinity at melanocortin receptors and shifted subtype preference across MC1R–MC5R. The same three residues have two identities: receptor-modulating inside a bigger peptide, receptor-independent alone.
How KPV blocks NF-κB: a transport step, not a kinase
KPV interrupts NF-κB signaling where the p65/RelA subunit is carried into the nucleus, not at the kinase that starts the cascade. In human bronchial epithelial cells, KPV binds the importin-alpha docking site on p65/RelA and prevents its nuclear import, so the transcription factor never reaches the genes it would otherwise switch on.
The canonical cascade runs: inflammatory stimulus → IKK activation → phosphorylation and degradation of IκBα → release of p65/RelA → importin-alpha carries it into the nucleus → transcription of TNF-alpha, IL-1β, IL-6 and IL-8. Land (2012), in the 16HBE14o- human bronchial epithelial line under TNF-alpha and respiratory syncytial virus stimulation, mapped where KPV cuts in:
- Total IκBα rose significantly with KPV, but the ratio of IKK-phosphorylated IκBα to total IκBα did not change — KPV is not blocking phosphorylation upstream; it stabilizes the IκBα pool downstream.
- Immunofluorescence with YFP-tagged p65RelA showed KPV abolished TNF-alpha-evoked nuclear import of the subunit.
- Competition binding showed a direct interaction between KPV and the importin-alpha-3 site on p65/RelA, consistent with blockade of the importin armadillo (ARM) domains 7 and 8; in silico Pepsite analysis against importin-alpha-2 predicted contacts between two or more KPV residues and amino acids 360–403, the stretch spanning those same repeats.
Downstream, Land reported dose-dependent reductions in IL-8 and eotaxin secretion and in matrix metalloproteinase-9 activity at nanomolar concentrations. KPV also inhibits MAP kinase signaling, specified as the ERK/p38 axis in keratinocytes. No comparative safety study against broader anti-inflammatory strategies has been published, so the mechanism is the claim here, not a safety advantage.
PepT1: inflammation opens KPV's own door
PepT1 (SLC15A1) is a proton-coupled transporter that normally performs concentrative uptake of dietary di- and tripeptides in the small intestine. KPV, being a tripeptide, is an excellent substrate for it — a property larger melanocortin peptides and full-length alpha-MSH do not share. That transporter is how KPV gets inside cells.
Dalmasso and colleagues (2008) established the axis. Using Caco2-BBE and HT29-Cl.19A human intestinal epithelial lines plus Jurkat human T cells, they showed PepT1-mediated uptake of KPV into both epithelial and immune cells. Raised intracellular KPV decreased NF-κB and MAP kinase activation and reduced IL-8 secretion at nanomolar concentrations — an order of magnitude, not a precise threshold.
The pathophysiological hook is the interesting part. PepT1 is normally a small-intestinal transporter, but it is induced in colonic epithelium during inflammatory bowel disease, so inflamed colon gains uptake capacity it does not normally have. Inflammation builds the door the molecule walks through. Cryo-EM structures of human PepT1 and PepT2 (Killer et al., 2021) explain its tolerance of such varied substrates.
Three colitis models, and one knockout arm
Two research groups tested KPV across three chemically and immunologically distinct mouse colitis models, plus a knockout arm that clarifies the mechanism. KPV was given orally throughout, with weight, colonic myeloperoxidase (MPO), histology and cytokine mRNA as the read-outs.
| Model | System | What was observed | Source |
|---|---|---|---|
| TNBS-induced colitis | Mice, KPV in drinking water | Reduced incidence, with decreased pro-inflammatory cytokine expression | Dalmasso 2008 |
| DSS-induced colitis | Mice, KPV in drinking water | Reduced incidence, by histology and cytokine mRNA | Dalmasso 2008 |
| DSS-induced colitis | Mice, oral KPV | Earlier recovery, stronger weight regain; reduced inflammatory infiltrate and colonic MPO | Kannengiesser 2008 |
| CD45RB-hi transfer colitis | Mice, T-cell transfer | Recovery, weight regain, reduced histological inflammation | Kannengiesser 2008 |
| DSS colitis in MC1Re/e mice | Mice with nonfunctional MC1R | All KPV-treated animals rescued from death; effect at least partly independent of MC1R signaling | Kannengiesser 2008 |
The knockout arm is the most informative row. MC1R is the receptor most associated with alpha-MSH's classical actions; run the experiment in animals whose MC1R does not work and the effect should disappear if it depends on that receptor. It did not. Read with the importin blockade and PepT1-mediated uptake, that is the argument that KPV acts inside cells, interfering with a transcription factor's commute rather than activating a surface receptor.
These remain model findings. Reduced MPO and cytokine mRNA in chemically induced mouse colitis is evidence about a mechanism, not evidence that a compounded peptide treats inflammatory bowel disease in a person.
If gut support is what brings you to peptides, the compound with the deeper file is not KPV. Promise's Gut Health & Digestion category is built around BPC-157, whose evidence base is also overwhelmingly preclinical: a 2025 systematic review counted 35 preclinical studies against one retrospective human series of 12 patients.
Outside the gut: airway, skin, and oral mucosa
KPV has been studied in three other tissue settings, all preclinical: bronchial epithelial cells (the Land work above — where the companion peptide γ-MSH, by contrast, required the MC3R receptor for its effect, sharpening the case that KPV's route is receptor-independent), human keratinocytes, and a rat model of chemotherapy-induced oral mucositis. The pattern is consistent — reduced cytokine output, dampened NF-κB signaling — in cell lines and rodents.
In skin, Elliott and colleagues (2004) showed KPV activates signaling pathways directly in human keratinocytes, and Sung and colleagues (2025) reported that in HaCaT keratinocytes challenged with fine particulate matter, KPV restored cell viability, reduced IL-1β secretion and inhibited reactive oxygen species production while attenuating ERK/p38 MAPK activation.
In the mouth, Shao and colleagues (2021) tested a mucoadhesive hydrogel carrying KPV in rats with chemotherapy-induced oral mucositis: the gel adhered to gingival mucosa for about seven hours, IL-1β and TNF-alpha fell while IL-10 rose, and the repair markers CK10 and PCNA increased. One attribution is often mangled here. The gel also showed antibacterial activity against S. aureus and in MRSA-infected wounds, but that belongs to the epigallocatechin gallate (EGCG) built into the matrix — not a demonstration that KPV is an antibiotic.
The delivery research is not a product
Most of the striking numbers in the KPV literature belong to engineered formulations — nanoparticles, hydrogels, prodrug conjugates — not to KPV in solution. They exist to solve one problem: free oral KPV faces gastrointestinal degradation and poor absorption. None is what a compounding pharmacy dispenses.
The best-known figure comes from Laroui and colleagues (2010), who loaded KPV into 400-nanometer PLA nanoparticles encapsulated in an alginate/chitosan hydrogel and reported, in DSS colitis mice, similar efficacy at a concentration 12,000-fold lower than free KPV in solution. Secondary write-ups often print that figure with a digit missing and attach it to a different nanoparticle paper; the formulation and citation above are the correct pairing.
Later platforms extend the idea. Xiao et al. (2017) made hyaluronic-acid-functionalized nanoparticles of about 272.3 nm and −5.3 mV zeta potential, targeted to colonic epithelium and macrophages and given orally inside a chitosan/alginate hydrogel — nontoxic and biocompatible in intestinal cells, with combined mucosal-healing and anti-inflammatory effects, and with the hydrogel-encapsulated version markedly outperforming the plain nanoparticle system at preventing mucosal damage and downregulating TNF-alpha. Zhang et al. (2024) co-assembled KPV with the immunosuppressant FK506 so the nanodrug homes to PepT1 where it is aberrantly expressed; in acute (2.5% DSS) and chronic (4% DSS) colitis it lowered MPO, nitric oxide, ROS, TNF-alpha, IL-1β and IL-6, and restored the tight-junction proteins Claudin-5, Occludin-1 and ZO-1 — a restoration that surpassed the free-KPV arm. On that endpoint the carrier did the heavy lifting. At the whole-animal level the same study recorded improved body weight, colon length and disease-activity index, and immunohistochemistry showed reduced CD68 (macrophage) and CD3 (T-lymphocyte) infiltration — the immune-cell-level readout behind the anti-inflammatory numbers. Cheng et al. (2026) built a conjugate that releases KPV in response to reactive oxygen species at inflamed sites, reporting 3.8-fold greater colonic accumulation and retained activity at a 20-fold lower dose. And Marotti et al. (2024) used hyaluronan–KPV conjugates on hybrid lipid nanoparticles loaded with teduglutide: endogenous GLP-2 production rose, anti-inflammatory targeting ran through CD44/TLR4 modulation, and a redox-responsive disulfide link released the payload at inflamed sites.
This literature says two things at once: KPV's mechanism interested enough groups to engineer around it, and plain KPV is hard to deliver, which is why they had to.
Where KPV sits in Promise's catalog
KPV is not a standalone product at Promise. It reaches the catalog as one of four compounds in the KLOW blend — BPC-157, TB-500, GHK-Cu and KPV — dispensed as a compounded medication prepared by a licensed U.S. pharmacy for an individual patient. A licensed provider reviews every request and prescribes or declines based on medical eligibility; not everyone qualifies.
One limit is worth stating plainly: no published study tests those four compounds together. Each has its own separate literature, and combining them is a formulation decision, not a tested synergy. What is in the blend, and the reasoning behind the combination, is covered in the companion article on the KLOW peptide blend.
What to watch as KPV research matures
The gap to watch is the obvious one: there is still no human study of KPV. Three developments would change the picture — a first human trial of plain KPV, clinical translation of any delivery platform, and evidence on whether free KPV can reach the barrier-protein endpoints only the nanocarrier arms have hit.
There is also a regulatory thread. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend KPV for the 503A bulk drug substances list. That vote is advisory and rulemaking is pending, so it changes nothing today — and a licensed provider may still prescribe; that decision is between you and your doctor.
The mechanism is what makes this compound worth following: block a transcription factor's ride into the nucleus, and ride into inflamed tissue on a transporter that inflammation itself switches on. Legible hypotheses are the ones that get tested in people.
This article is educational and is not medical advice. Whether any compounded peptide is appropriate for you is a decision to make with a licensed provider.